About: Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 04 March 2011

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) наукова стаття, опублікована в березні 2011 (uk) artículu científicu espublizáu en marzu de 2011 (ast) scientific article published on 04 March 2011 (en) مقالة علمية نشرت في 04 مارس 2011 (ar)
publication date	wds:Q37850188-F4C702EC-CB75-4A1F-B270-ABC52827F385
publication date	2011-03-04 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37850188-6E9134C6-DF84-47C0-85B5-E439AB0A7E1A
language of work or name	English
cites work	wds:Q37850188-05B19069-AA21-469E-959E-19260D10D11E wds:Q37850188-0E764A01-0A4C-4D58-9E30-A5FD0B577697 wds:Q37850188-1C91D863-4CED-4F0E-A84E-624967E3AF26 wds:Q37850188-3DC9D369-B007-41AD-BD4F-191E61379459 wds:Q37850188-4A29F256-3800-4EAE-B738-DDB04E402A23 wds:Q37850188-4B872B12-D0FF-4C4A-91A0-011BA635CC7B wds:Q37850188-4D383037-98D2-47FD-BBC5-8EDD9AE32EBD wds:Q37850188-53CC630F-979B-4128-855F-3628167A5997 wds:Q37850188-5CD6DD4A-444B-4F12-AD1D-F66F179A0F9F wds:Q37850188-62D3A1EF-18F1-4DB3-8448-BE333BE33D16 wds:Q37850188-6C62E577-8BB2-4B4D-B856-0BDD923B5DDC wds:Q37850188-724A98A2-AB74-4504-9BA3-C6DA64F65176 wds:Q37850188-77DCA969-A813-466E-ACB6-057132F2F861 wds:Q37850188-8785BB7C-1A4F-4F3C-B32F-FFCD1C073515 wds:Q37850188-8C288D3C-A8F5-4B76-8016-577D1ADF7A9F wds:Q37850188-8D9A4C5D-73EA-43D8-B9EE-E2A5E4823AA8 wds:Q37850188-8E02E6F3-D799-4864-B099-48EF6552106F wds:Q37850188-A5D8EF05-7912-4FB9-8D52-D148D880F951 wds:Q37850188-B19CA1E2-0FE0-4444-8A75-F06FF09B423D wds:Q37850188-B5071A0B-4877-4A86-9B0E-8024B41E1A42 wds:Q37850188-C96E521B-1C05-4AC6-B77C-18AAE289CEBD wds:Q37850188-CA2045C9-1345-4B3F-A7CB-D07D5FC116FE wds:Q37850188-D704A5F1-81C5-4499-9945-6E849ED6472B wds:Q37850188-E6522FA1-9F47-42DF-A30F-EB5937A5CEA0 wds:Q37850188-FA3D73D6-1203-42F0-A434-A09E4C0F4570 wds:Q37850188-FA654373-47FF-44B7-88C7-00B944CBB4E5
cites work	Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225 Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy RETRACTED: The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada Platinum-based chemotherapy plus cetuximab in head and neck cancer Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390) Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study Head and neck cancer A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution
author name string	wds:Q37850188-63542317-DC1A-42A4-AFD6-42C775544A6E wds:Q37850188-83478B5D-14A9-4B34-B059-097C3FC4777A wds:Q37850188-B2F1DE64-0F81-465E-ADD2-6F9FA4C762A9 wds:Q37850188-B791708D-94BA-4DF4-84F9-435215AB080F wds:Q37850188-CAC4B83D-8A2A-4410-9275-9D0C4CD4328E wds:Q37850188-CF540595-C8F4-4BBE-9177-18E33629742F wds:Q37850188-DF8613D8-F7DA-4B3D-B768-71070B3DAE27 wds:Q37850188-E6C2EA99-68E6-48E1-A2C6-CBC25DB4926D wds:Q37850188-EDE1B458-7170-4393-862B-0AE4CD0B269D wds:Q37850188-FF2A68AA-3EDB-4FBC-8F1B-46180D2ABECF
author name string	Steen Lisby Tina Nielsen Jean-Pascal Machiels Per Sørensen Paul M J Clement Agnes Ruzsa Annika Flygare Gabor Repassy Igor Lifirenko Somasundaram Subramanian
rdfs:label	Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial (en) Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial (nl)
skos:prefLabel	Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial (en) Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial (nl)
name	Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial (en) Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial (nl)
title	wds:Q37850188-A48235E7-2201-453C-8169-0CDB2F71C415

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software